Experimental CAR-T therapy targets Hard-to-Treat lymphoma
NCT ID NCT07447726
First seen Mar 12, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This early-phase study tests a new type of CAR-T cell therapy (CD19X) in 3 people with large B-cell lymphoma that has returned or not responded to standard treatment. The main goal is to check safety, looking for side effects like immune reactions or nerve problems. Researchers will also see if the treatment shrinks tumors or leads to remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.